prioriti review week octob
may miss past week
 realli valu time case miss anyth provid quick summari major event past eek
key event atch upcom eek also link research model applic highlight
frequent inbound question debat topic come investor minut read pleas let us
presid trump provid plan limit medicar part spend expand blueprint introduc last may administr
intend start pilot program reduc part spend hich includ propos reimburs drug base intern
price index biopharmaceut thought brief part propos biopharmaceut
 thought presid drug price follow -up
eisai present updat alzheim program ctad eisai includ subgroup analysi phase studi
 hile provid fix dose lte titrat lte data aducanumab phase prime
thought aducanumab prime ctad updat thought ctad updat
fda issu regeneron pre-fil eylea syring agenc instead ask regeneron small studi
demonstr abil doctor administ formul manag indic decis unlik impact
potenti launch next year given plan resubmit applic earli
vertex competitor galapago report falcon cf data restructur agreement falcon studi galapago first
 holly-intern develop tripl combo cystic fibrosi treatment increas ppfev decreas sw eat chlorid
mmol/l galapago also restructur deal ith partner ith latter obtain exclus orldw ide right former
cf portfolio exchang up-front mileston royalti thought galapago falcon cf
acquir skin-car compani ci hold cash deal ci portfolio dermocosmet cosmet
skincar product mark jnj latest invest consum busi turn-around effort hich also includ acquisit
zarbe natur summer alreadi second largest sharehold compani expect launch tender
offer octob close analyst day consum session updat
reduc list price repatha ould avail list price per year accord
medicar patient abandon prescript current despit approv rate due averag co-pay rang
script comparison commerci plan thought repatha price cut
submit bla viaskin peanut announc start phase toddler applic cover peanut allergi
treatment children year despit posit numer trend pivot phase pepit miss primari endpoint due
statist confid interv ever fda later indic second phase ould requir separ compani
announc start part pepit hich set includ toddler year age dbvt fda show dbvt littl
lilli report posit outcom two phase taltz ankylos spondyl detail coast-v link publish data
coast-w link ere present acr meet ith taltz result statist improv eek vs
placeboin addit secondari endpoint includ mri spine sparcc accord lilli coast-v
repres first trial success use
report posit phase follow-up data stelara sle data present acr meet reveal benefit
patient continu take stelara eek placebo control portion trial one year met respons criteria
vs cross placebo among patient stelara entir year major also experienc sustain benefit
measur ith increas respons rate measur clasi safeti profil consist ith
previou stelara studi phase sle initi
bain capit set neuroscience-focus compani contribut programsthe alreadi
clinical-stag developmentfrom discontinu neurosci portfolio ith fund suppli bain exchang
 ill retain new compani thought neurosci reorgan
celgen revlimid improv smolder mm ecog open-label phase sponsor nci revlimid reportedli
lead statist signific improv observ asymptomat smolder multipl myelomath primari
endpoint detail studi ill present later medic meet
feder circuit affirm rule forward pharma tecfidera patent case march ptab rule
forw ard interfer case ith patent interfer although previous licens forw ard ip
decis mean pay forw ard royalti in us ptab interfer vs forw ard
pharma thought tecfidera settlement ith forw ard pharma
lilly/ report posit safeti data long-term follow-up olumi ra studi long-term safeti data collect
random studi one lte reveal ae incid rate consist ith previou safeti dataw ith evid increas risk
due extend treatment per patient year incid risk malign excl non-melanoma skin cancer mace
 seriou infect vte
fda accept biohaven ind first patient dose biohaven next-gener small molecul anti-cgrp
receptor antagonist current formul intranas administr biohaven plan file nda small molecul cgrp
inhibitor rimegep
report initi posit data phase prevent vaccin eek tetraval mosaic viral vector
report ell toler elicit greater breath immun respons differ strain vs trival mosaic vector
travers studi efficaci tetraval vaccin current assess large-scal studi
alexion collabor dicerna rnai-therapi complement-medi diseas term agreement
alexion ill licens develop tw preclin candid leverag dicerna galxc platform ith option tw addit
assetsin exchang up-front payment equiti invest addit mileston royalti
collplant collabor print organ term agreement collplant ill grant unit
exclus licens technolog bioprint lung organ transplant ith former provid materi latter
exchang collplant ill receiv up-front oper regulatori mileston payment may occur
unit opt pursu organ collplant also elig receiv royalti commerci sale
ucb announc dapirolizumab pegol phase lupu studi miss primari endpoint dapirolizumab pegol
pegyl fab narrow ly miss primari endpoint bicla scale phase dose respons studi moderate-to-
sever activ system lupu erythematosu sle detail ere provid although studi author indic consist
potenti relev improv number clinic endpoint
myovant complet enrol phase relugolix prostat cancer studi compani expect report top-lin data hero
 ith nda submiss
proprietari research past week includ coverag earn
idea navig earn
inc initi overw eight
 biopharmaceut updat esmo congress
 final updat nacfc meet
 thought dupix asthma approv
bmy/mrk thought regulatori updat
gilead scienc thought call
seattl genet thought call
celgen corp thought call
bristol-my squibb thought call
merck co thought call
vertex pharmaceut thought call
alexion pharmaceut thought call
thought call
johnson johnson thought call
 biopharmaceut read-through novarti earn
 biopharmaceut read-through roch earn call
 biopharmaceut earn tracker snapshot eek
 biopharmaceut quot biopharma earn eek
client ask
investor ask follow ing topic phone call email in-person market meet
major takeaway first major week earn eek ed character sentiment tow ard
biopharma trend neg head view still posit favor pharma divers busi mix
smid biotech innov cycl neg tow ard larg cap biotech profit mid cap fundament perspect
risk profil seem low er especi drug price speech polici recommend fairli benign addit
earn hasnt terriblealthough guidanc rais dont impli much acceler given sector sentiment fall
go ed recommend merck lilli pharma celgen gilead larger cap biotech alexion neurocrin among
smid cap although ed also argu today volatil seattl overdon idea navig earn
implic administr propos address medicar part spend hile specif plan
 hich seek save next five yearsstil need final possibl implement still believ
plan materi unlik broadli impact biopharma market rather given scopei hospital/clin administ single-
sourc agentsth impact like felt acut specif therapi area includ oncolog ophthalmolog
mid-term given year timelin model follow ed presum roll-out rest nation thereaft absent
broader-focus reform includ greater restrict pbm establish pathw ay biosimilar introduct use
limit patent/ ip/ exclus claim see littl restrict overal pharmaceut price
takeaway biogen/eisai alzheim present overal thought updat aducanumab
phase prime data eisai subgroup ere help although data view unlik de-risk asset
mollifi critic amyloid hypothesi hile note favor trend studi increas question regard efficaci
antibodiesand inde relev amyloid hypothesisar like linger absent data larger clinic studi
watch week ahead
clinic trial read-out regulatori event expect near-term
phase data expect
phase data opdivo opdivo yervoy mainten sclc expect
american academi ophthalmolog chicago il octob
intern symposium hodgkin lymphoma ishl cologn germani octob
societi neurosci sfn san diego ca novemb
societi immunotherapi cancer ashington dc novemb
american societi hematolog san diego ca decemb
let us know question comment geoff jason olivia
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
